The most important financial indicators for the company Pharma Sa - Unique Identification Number 13591928:
sales in 2023 was
38.275.923
euro, registering a net profit of
477.088
euro and having an average number of
161
employees.
Firma isi desfasoara activitatea in domeniul Comert cu ridicata al produselor farmaceutice having the NACE code 4646.
Sales, Profit, Employees, Debts, Capitals, Financial Results -
Pharma Sa
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Sales - EUR
23.108.199
26.266.231
28.055.096
26.016.067
23.320.397
26.527.793
28.970.056
33.239.886
37.201.031
38.275.923
Total Income - EUR
23.161.313
26.359.618
28.140.602
26.139.213
23.345.730
26.630.253
28.999.203
33.294.266
37.247.734
38.417.516
Total Expenses - EUR
22.512.959
25.862.896
27.514.406
25.620.180
22.897.887
26.168.511
28.647.368
32.543.058
36.797.350
37.882.439
Gross Profit/Loss - EUR
648.354
496.722
626.196
519.032
447.844
461.742
351.834
751.208
450.384
535.077
Net Profit/Loss - EUR
461.561
443.317
551.287
423.224
405.204
389.695
275.540
611.402
417.163
477.088
Employees
156
153
139
137
135
143
147
161
169
161
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.
In the last year of activity, the sales increased by 3.2%, from 37.201.031 euro in the year 2022, to 38.275.923 euro in 2023.
The Net Profit increased by 61.191 euro, from 417.163 euro in 2022, to 477.088 in the last year.
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Pharma Sa - CUI 13591928
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Fixed Assets
3.522.285
3.216.759
3.166.834
2.915.272
3.039.818
3.304.655
3.548.566
5.034.397
5.203.425
5.101.827
Current Assets
22.395.838
23.455.473
24.106.498
24.800.238
23.854.608
26.617.632
25.685.205
24.285.049
21.337.533
23.238.255
Inventories
11.566.702
12.656.896
13.675.415
14.372.719
14.558.645
15.374.219
12.831.131
10.489.998
8.172.319
9.450.970
Receivables
10.511.191
9.974.241
10.069.554
10.111.034
9.004.505
10.199.984
11.966.572
12.595.940
12.636.341
13.147.399
Cash
317.945
824.336
361.529
316.484
291.458
1.043.430
887.501
1.199.111
528.873
639.886
Shareholders Funds
3.093.565
3.562.702
4.077.654
4.380.935
4.712.906
5.011.648
5.052.633
7.046.248
7.470.372
7.924.807
Social Capital
44.622
44.994
44.535
43.782
42.978
42.146
41.347
40.430
40.556
40.433
Debts
22.848.638
23.131.811
23.218.764
23.248.338
22.194.073
24.929.159
24.211.542
22.309.719
19.108.596
20.486.420
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
4.4821
Main CAEN
"4646 - 4646"
CAEN Financial Year
4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
23.238.255 euro in 2023 which includes Inventories of
9.450.970 euro, Receivables of
13.147.399 euro and cash availability of
639.886 euro.
The company's Equity was valued at
7.924.807 euro, while total Liabilities amounted to
20.486.420 euro.
Equity increased by 477.088 euro, from 7.470.372 euro in 2022, to 7.924.807 in 2023.
Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Pharma Sa